Oryzon Genomics S.A. (BME:ORY)

Oryzon Genomics Income Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	10.93	7.36	14.19	15.7	10.62
Revenue Growth (YoY)	48.59%	-48.15%	-9.60%	47.88%	11.49%
Cost of Revenue	0.28	0.3	0.24	0.46	0.75
Gross Profit	10.65	7.06	13.95	15.23	9.87
Selling, General & Admin	3.79	3.55	3.61	3.57	3.67
Other Operating Expenses	12.44	7.86	14.75	17	13.07
Operating Expenses	16.36	11.56	18.51	20.73	16.88
Operating Income	-5.71	-4.5	-4.56	-5.5	-7.01
Interest Expense	-0	-0	-1.89	-1.12	-0.46
Interest & Investment Income	0.71	0.2	0.03	0.01	0.01
Currency Exchange Gain (Loss)	0.05	-0.09	0.1	0.24	0.28
Other Non Operating Income (Expenses)	-0.65	-1.17	0.2	-0.2	0
EBT Excluding Unusual Items	-5.6	-5.56	-6.12	-6.56	-7.18
Gain (Loss) on Sale of Assets	-	-	-	-	-0
Asset Writedown	-0	-	-	-	-
Other Unusual Items	0.01	0.08	0.01	0.01	0.01
Pretax Income	-5.6	-5.48	-6.1	-6.56	-7.18
Income Tax Expense	-2.99	-1.91	-2.75	-2.33	-2.49
Net Income	-2.61	-3.58	-3.35	-4.23	-4.69
Net Income to Common	-2.61	-3.58	-3.35	-4.23	-4.69
Shares Outstanding (Basic)	78	65	61	55	53
Shares Outstanding (Diluted)	78	65	61	55	53
Shares Change (YoY)	19.72%	6.35%	10.10%	4.80%	-
EPS (Basic)	-0.03	-0.06	-0.06	-0.08	-0.09
EPS (Diluted)	-0.03	-0.06	-0.06	-0.08	-0.09
Free Cash Flow	-2.42	-5.79	-0.57	-1.92	-3.8
Free Cash Flow Per Share	-0.03	-0.09	-0.01	-0.04	-0.07
Gross Margin	97.42%	95.89%	98.28%	97.04%	92.97%
Operating Margin	-52.25%	-61.18%	-32.16%	-35.02%	-66.07%
Profit Margin	-23.83%	-48.62%	-23.63%	-26.96%	-44.15%
Free Cash Flow Margin	-22.09%	-78.70%	-4.05%	-12.25%	-35.82%
EBITDA	-5.6	-4.38	-4.43	-5.35	-6.88
EBITDA Margin	-51.19%	-59.47%	-31.24%	-34.08%	-64.81%
D&A For EBITDA	0.12	0.13	0.13	0.15	0.13
EBIT	-5.71	-4.5	-4.56	-5.5	-7.01
EBIT Margin	-52.25%	-61.18%	-32.16%	-35.02%	-66.07%

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.